Toujeo SoloStar
Generic Name
Insulin Glargine (rDNA origin) U300
Manufacturer
Sanofi
Country
France, Germany
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| toujeo solostar 300 iu injection | ৳ 2,305.00 | N/A |
Description
Overview of the medicine
Toujeo SoloStar contains insulin glargine U300, a long-acting human insulin analog, used to improve glycemic control in adults and children (6 years and older) with diabetes mellitus.
Uses & Indications
Dosage
Adults
Individualized. Usually initiated at 0.2 units/kg once daily for type 1 diabetes or 0.2 units/kg once daily for type 2 diabetes, adjusted based on blood glucose levels. Doses are typically 10-18% lower when converting from Lantus U100 to Toujeo U300.
Elderly
No specific dose adjustment required, but close monitoring of blood glucose is recommended due to potential for greater insulin sensitivity and risk of hypoglycemia.
Renal_impairment
No specific dose adjustment for insulin glargine is required in patients with renal impairment, but blood glucose monitoring should be intensified, and the insulin dose adjusted individually.
How to Take
Administer subcutaneously once daily at any time of day, but at the same time each day. Do not administer intravenously. Rotate injection sites within the same region (abdomen, thigh, or deltoid) to reduce the risk of lipodystrophy.
Mechanism of Action
Insulin glargine lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Pharmacokinetics
Onset
Onset of action typically within 6 hours.
Excretion
Metabolites primarily excreted renally.
Half life
Terminal half-life is approximately 18-19 hours.
Absorption
Slow and prolonged absorption from subcutaneous injection site, resulting in a relatively constant concentration-time profile over 36 hours.
Metabolism
Partially metabolized in the subcutaneous tissue to two active metabolites (M1 and M2). Primarily metabolized in the liver.
Side Effects
Contraindications
- Hypersensitivity to insulin glargine or any excipient.
- During episodes of hypoglycemia.
Drug Interactions
Oral antidiabetic agents, GLP-1 receptor agonists, ACE inhibitors, angiotensin receptor blockers, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics
May increase insulin's glucose-lowering effect and risk of hypoglycemia.
Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, growth hormone, isoniazid, niacin, oral contraceptives, phenothiazine derivatives, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones
May decrease insulin's glucose-lowering effect.
Storage
Unopened: Refrigerate (2°C-8°C). Do not freeze. Opened: Store at room temperature (below 30°C) and use within 56 days. Protect from light and heat. Do not refrigerate opened pens.
Overdose
Symptoms of overdose include severe hypoglycemia, which can lead to neurological impairment, seizures, and coma. Management: Mild hypoglycemia can be treated with oral glucose. Severe hypoglycemia requires parenteral glucose (IV dextrose or IM/subcutaneous glucagon) and immediate medical attention.
Pregnancy & Lactation
Pregnancy: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Closely monitor blood glucose. Lactation: Insulin glargine is generally considered compatible with breastfeeding, but consult a healthcare professional.
Side Effects
Contraindications
- Hypersensitivity to insulin glargine or any excipient.
- During episodes of hypoglycemia.
Drug Interactions
Oral antidiabetic agents, GLP-1 receptor agonists, ACE inhibitors, angiotensin receptor blockers, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics
May increase insulin's glucose-lowering effect and risk of hypoglycemia.
Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, growth hormone, isoniazid, niacin, oral contraceptives, phenothiazine derivatives, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones
May decrease insulin's glucose-lowering effect.
Storage
Unopened: Refrigerate (2°C-8°C). Do not freeze. Opened: Store at room temperature (below 30°C) and use within 56 days. Protect from light and heat. Do not refrigerate opened pens.
Overdose
Symptoms of overdose include severe hypoglycemia, which can lead to neurological impairment, seizures, and coma. Management: Mild hypoglycemia can be treated with oral glucose. Severe hypoglycemia requires parenteral glucose (IV dextrose or IM/subcutaneous glucagon) and immediate medical attention.
Pregnancy & Lactation
Pregnancy: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Closely monitor blood glucose. Lactation: Insulin glargine is generally considered compatible with breastfeeding, but consult a healthcare professional.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Refer to product packaging, typically 2-3 years for unopened, and 56 days for opened pens.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented
WHO Essential Medicine
YesClinical Trials
Toujeo was approved based on the EDITION clinical trial program, demonstrating similar glycemic control with a reduced risk of nocturnal hypoglycemia compared to U100 glargine, particularly in Type 2 diabetes.
Lab Monitoring
- Fasting plasma glucose (FPG)
- HbA1c
- Blood glucose self-monitoring
Doctor Notes
- Educate patients on proper injection technique and site rotation.
- Emphasize the importance of blood glucose monitoring and timely dose adjustments.
- Be aware of the risk of hypoglycemia, especially nocturnal, and provide rescue instructions.
- For patients converting from U100 insulin glargine, a dose reduction of 10-18% may be considered to minimize the risk of hypoglycemia.
Patient Guidelines
- Always check the insulin label before each injection to avoid medication errors.
- Never share your SoloStar pen with other people, even if the needle is changed, to avoid transmission of infection.
- Always carry fast-acting carbohydrates to treat hypoglycemia and know the symptoms.
Missed Dose Advice
If a dose is missed, take it as soon as you remember, then resume your regular schedule. Do not take a double dose to make up for a missed one. Consult your doctor for specific advice.
Driving Precautions
Patients should be advised to take precautions to avoid hypoglycemia while driving or operating machinery. Hypoglycemia may impair the ability to concentrate and react.
Lifestyle Advice
- Maintain a balanced diet and consistent meal times.
- Engage in regular physical activity as advised by your doctor.
- Monitor blood glucose regularly and record results.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.